Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog.

Amneal is seeking to get its DHE autoinjector approved for the acute treatment of migraine with or without aura and cluster headaches in adults. The FDA is expected to complete its review of the ...

BRIDGEWATER, N.J., November 21, 2024--Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist BRIDGEWATER ...

A replay of the webcast will be available following the event. Source: Amneal Pharmaceuticals, Inc. The views and opinions expressed herein are the views and opinions of the author and do not ...

Generic Drug-Focused Amneal Beats Q3 Expectations, Reaffirms Annual Forecasts Amneal Pharmaceuticals Q3 sales rose 13% to $702.47 million, beating estimates. EPS hit $0.16, above consensus ...

On Friday, Amneal Pharmaceuticals Inc (NASDAQ:AMRX) reported third-quarter adjusted EPS of $0.16, down from $0.19 a year ago, beating the consensus of $0.14. The company reported sales of $702.47 ...

"The hydroxychloroquine donation by Amneal comes at an important time. The Louisiana Board of Pharmacy has noted serious concerns over the availability of this drug and has issued specific ...

A live webcast will be accessible on the Company's website at https://investors.amneal.com. A replay of the webcast will be available following the event. Amneal Pharmaceuticals, Inc. (Nasdaq ...